Compare INTT & COEP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | INTT | COEP |
|---|---|---|
| Founded | 1981 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 94.9M | 100.4M |
| IPO Year | 1997 | N/A |
| Metric | INTT | COEP |
|---|---|---|
| Price | $7.52 | $14.65 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $12.00 | N/A |
| AVG Volume (30 Days) | 34.5K | ★ 117.0K |
| Earning Date | 11-05-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $117,606,000.00 | $500,996.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $9.60 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $5.24 | $2.31 |
| 52 Week High | $9.77 | $21.41 |
| Indicator | INTT | COEP |
|---|---|---|
| Relative Strength Index (RSI) | 47.29 | 43.24 |
| Support Level | $7.12 | $13.61 |
| Resistance Level | $7.62 | $15.40 |
| Average True Range (ATR) | 0.34 | 1.07 |
| MACD | 0.00 | -0.09 |
| Stochastic Oscillator | 44.09 | 29.77 |
inTest Corp is a supplier of test and process solutions for use in manufacturing and testing across a range of markets including automotive, defense/aerospace, industrial, medical, semiconductor and telecommunications. The company manages its business as three operating segments which is also their reporting units that includes Electronic Test, Environmental Technologies and Process Technologies. Electronic Test (which includes semiconductor test equipment, flying probe and in-circuit testers), Environmental Technologies (which includes its thermal test, process and storage products) and Process Technologies (which includes induction heating and video imaging products). The company operates their business and sells its products both domestically and internationally.
Coeptis Therapeutics Holdings Inc is a biopharmaceutical company developing cell therapy platforms for patients with cancer. The company's product portfolio consists of multi-antigen CAR T technology licensed from the University of Pittsburgh (SNAP-CAR), a cell therapy technology (CD38-GEAR-NK), and an in vitro diagnostic (CD38-Diagnostic) targeting CD38-related cancers, which the company is developing with VyGen-Bio and medical researchers at the Karolinska Institutet.